IGI Logo

JB Chemicals & Pharmaceuticals is currently trading at Rs. 1472.90, up by 6.80 points or 0.46% from its previous closing of Rs. 1466.10 on the BSE.

The scrip opened at Rs. 1492.85 and has touched a high and low of Rs. 1498.95 and Rs. 1472.25 respectively. So far 2211 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1554.80 on 07-Dec-2023 and a 52 week low of Rs. 914.65 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 1510.50 and Rs. 1399.95 respectively. The current market cap of the company is Rs. 22919.40 crore.

The promoters holding in the company stood at 53.86%, while Institutions and Non-Institutions held 28.63% and 17.51% respectively.

JB Chemicals & Pharmaceuticals has received approval for execution of a Trade Mark License agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027. The Board also approved the promotion & distribution agreement with Novartis Healthcare for the same portfolio of select ophthalmology brands for the Indian market for a period of three years starting December 2023. JB Pharma shall offer employment to the impacted associates working on these ophthalmology brands.

Ophthalmology is one of the fastest growing therapies in the Indian Pharma market and this deal will catapult JB Pharma to among the leading players in the ophthalmology segment. The Board of Directors of J. B. Chemicals & Pharmaceuticals at its meeting held on December 19, 2023 has approved the same. 

JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).